# 1 Short report

# Dietary n-6 to n-3 fatty acid ratio is related to liver fat content independent of genetic effects: evidence from the monozygotic co-twin control design

- 4 Leonie H. Bogl<sup>1,2</sup>, Jaakko Kaprio<sup>2,3</sup>, Kirsi H. Pietiläinen<sup>4,5</sup>
- <sup>5</sup> <sup>1</sup>Department of Epidemiology, Center for Public Health, Medical University of Vienna,
- 6 Kinderspitalgasse 15, 1090, Vienna, Austria
- 7 leonie-helen.bogl@meduniwien.ac.at
- 8 <sup>2</sup>Institute for Molecular Medicine FIMM, University of Helsinki, 00014, Helsinki, Finland
- <sup>3</sup>Department of Public Health, University of Helsinki, 00014, Helsinki, Finland
- <sup>4</sup>Obesity Research Unit, Research Programs Unit, Diabetes and Obesity Research Program,
   University of Helsinki, 00014, Helsinki, Finland
- <sup>5</sup>Abdominal Center, Endocrinology, Helsinki University Central Hospital and University of
- 13 Helsinki, 00014, Helsinki, Finland
- 14
- 15 **Words:** 1454 including the abstract, excluding references
- 16 Keywords: identical twins; twin study; liver fat; nutrition; omega-6: omega-3 ratio

#### 17 Abstract

Background & aim: Lifestyle changes focusing on diet and exercise remain the cornerstone of the treatment of non-alcoholic fatty liver disease (NAFLD). The present co-twin control study of monozygotic (MZ) twin pairs was designed to identify nutritional factors potentially involved in the pathogenesis of NAFLD.

- 22 Methods: Cross-sectional study of 50 MZ twin pairs (age range: 23-36 years), of which ten pairs were
- 23 discordant for liver fat (liver fat percentage of one twin  $\leq$  5% and his/her co-twin > 5% and a
- 24 difference between co-twins of > 5%) as determined by magnetic resonance spectroscopy. Nutrient
- 25 intake was calculated from 3-day food records.

Results: Among the ten liver fat-discordant twin pairs, the n-6: n-3 ratio was significantly higher in the twins with higher liver as compared to their co-twins with lower liver fat (6.6: 1 vs. 3.2: 1, *p*-value = 0.005). In multiple regression analysis of within-pair differences including all 50 twin pairs, a higher n-6: n-3 ratio was significantly associated with a higher liver fat percentage within MZ twin pairs after adjustment for body mass index, energy intake and other covariates (standardized beta= 0.43, *p*-value = 0.001).

32 Conclusions: Our findings suggest that the n-6: n-3 ratio is a promising dietary agent for the 33 prevention and treatment of NAFLD. Clinical trials are required to better understand causal 34 relationships and required doses.

35

#### 36 Introduction

Non-alcoholic fatty liver disease (NAFLD), characterized by fat accumulation in more than 5% of hepatocytes in the absence of excessive alcohol consumption, is the most common chronic liver disease in the world. It affects up to a quarter of the general population, depending on the country studied<sup>1</sup>. The disease spectrum includes simple steatosis, steatohepatitis, advanced fibrosis and cirrhosis which can progress to liver failure<sup>1</sup>.

The heritability of NAFLD is low, underscoring the importance of environmental factors in its etiology<sup>2</sup>. Currently, there are no approved pharmacotherapies for patients with NAFLD. Therefore, weight reduction and lifestyle changes through diet and exercise form the first-line therapy for treatment<sup>3</sup>. Diets high in saturated fatty acids and refined carbohydrates could exacerbate NAFLD<sup>4</sup>, while Mediterranean dietary patterns might reduce liver fat even in the absence of weight loss<sup>5</sup>. Randomized controlled trials suggest that supplementation with omega-3 (n-3) polyunsaturated fatty acids (PUFAs) has therapeutic potential for treating patients with NAFLD <sup>6</sup>.

Another powerful study design that allows stronger inference about causality than observational studies of unrelated individuals is the co-twin-control design of disease-discordant monozygotic (MZ) twin pairs because MZ twins are genetically identical at the DNA sequence level and discordance within pairs must thus be of environmental origin. Our previous twin study suggests that metabolic abnormalities in acquired obesity are tightly linked to liver fat content<sup>7</sup>. The present study of MZ twins was designed to identify nutritional factors potentially involved in the pathogenesis of NAFLD.

#### 56 **Research design and methods**

57 TwinFat study participants were enrolled from two Finnish population-based longitudinal studies of

- 58 five consecutive birth cohorts of young adult twins<sup>8</sup>. Participants were invited to the TwinFat study 59 based on their reported body mass index (BMI) during these studies (at the age of 23 to 27 years)
- 60 with the aim to represent a wide range of intra-pair differences in BMI. Participants were then
- 61 weighed and their height was measured while barefoot and in light clothing by trained research
- 62 nurses. Whole-body fat was measured by dual energy x-ray absorptiometry, abdominal
- 63 subcutaneous and intra-abdominal fat by magnetic resonance imaging and liver fat percentage by
- 64 magnetic resonance spectroscopy as described earlier<sup>9</sup>. The homeostasis model assessment of
- 65 insulin resistance (HOMA-IR) was calculated based on 2-hour oral glucose tolerance tests. Fasting
- 66 plasma cholesterol and triglyceride concentrations were determined with enzymatic methods.
- 67 Supine blood pressure was measured using an automatic digital sphygmomanometer (mean of three
- 68 measurements).

69 Nutrient intake was calculated from 3-day food records by the Diet32 program (Aivo), based on a national Finnish database (Fineli, www.fineli.fi, National Institute for Health and Welfare, Nutrition 70 71 Unit, Helsinki, Finland). The sports activity index was calculated from the Baecke questionnaire<sup>10</sup>. 72 Out of 107 twin individuals with data on liver fat and food records, one twin individual was excluded 73 because of missing information on physical activity, two twin individuals because of implausible 74 energy intakes (one woman reported < 714 kcal/day, and one men > 4200 kcal/day) and another four 75 twin individuals because of missing co-twin information. Thus, the final analytic sample consisted of 76 50 MZ twin pairs, of which 10 twin pairs were discordant for liver fat. Liver fat discordance was 77 defined as the liver fat percentage of one twin  $\leq$  5% and his/her co-twin > 5% and a difference between 78 co-twins of > 5% resulting in identification of ten such pairs. The study protocol was in accordance 79 with the Helsinki Declaration and approved by local Ethical Committees. Written informed consent

80 was given by all twins.

B1 Data were reported as median and interquartile ranges. Differences between discordant twin pairs B2 were analysed using Wilcoxon signed rank test. In all twin pairs, multiple linear regression analysis B3 was used to relate within-pair differences in log transformed liver fat to within-pair differences in the B4 omega-6 (n-6) to n-3 ratio adjusted for covariates. Statistical analyses were performed using B5 State variant 12 (State Corr. Collage Station, TX)

85 Stata version 13 (Stata Corp, College Station, TX).

#### 86 **Results**

87 The descriptive characteristics (clinical, behavioral, nutritional and liver fat) of the 100 twin individuals (mean age 29.9 years (range: 23-36 years) and of the subset of ten liver fat-discordant 88 twin pairs are shown in Table 1. Among these ten pairs, the twins with higher liver fat had more body 89 90 fat and a worse metabolic profile than their co-twins with lower liver fat. The twins with higher and 91 lower liver fat did not differ in physical activity indices and energy intake, or the intake of protein, 92 fat and carbohydrates. In every single discordant pair, the twin with the higher liver fat percentage 93 had consistently a higher n-6: n-3 ratio than his or her co-twin with less liver fat (Supplementary 94 Figure). The twins with the lower liver fat percentage had a mean n-6: n-3 ratio of 3.2: 1, while the 95 ratio in the co-twins with higher liver fat percentage was 6.6: 1 (p-value = 0.005 for the difference 96 between pairs).

97 The results from the within-pair linear regression on all 50 MZ pairs are presented in Table 2. The n-

98 6: n-3 ratio and BMI were significant predictors and of about equal importance in predicting within-

99 pair differences in liver fat. The gender interaction (male vs. female pairs) was not significant. 100 Additional adjustment for intra-abdominal fat (standardized beta= 0.37, p=0.08) did not change the

Additional adjustment for intra-abdominal fat (standardized beta= 0.37, p=0.08) did not change the effect estimate for the n-6: n-3 ratio (standardized beta= 0.39, *p*-value = 0.002), but removed the

influence of BMI (standardized beta= 0.13, *p*-value = 0.52). In a model that additionally adjusted for

sucrose, the effect size for sucrose was not significant (standardized beta = -0.12, *p*-value = 0.28), and

104 the effect estimate for the n-6: n-3 ratio remained unchanged (standardized beta= 0.40, p-value =

105 0.001).

# 106 **Discussion**

To our knowledge, this is the first study that evaluated nutrient intake differences in MZ twin pairs discordant for liver fat. Among the 10 twin pairs discordant for liver fat, the co-twins with higher liver fat reported a higher dietary n-6: n-3 ratio than his or her co-twin in every single pair. We employed the MZ co-twin control design, which is analogue to a case-control study, where the twin with the higher liver fat is the case and the co-twin with the lower liver fat the control, with the additional advantage that cases and controls are naturally matched for several factors including age, sex and genotype.

Due to modern agriculture and the popularity of fast foods, Western diets contain excessive amounts of n-6 PUFAs and low amounts of n-3 PUFAs. An overconsumption of n-6 PUFAs coupled with under-consumption of n-3 PUFAs may lead to inflammation and pro-inflammatory cytokine production involved in many disease processes<sup>11</sup>. In addition, n-3 PUFAs may influence the intestinal microbiota<sup>12</sup> and thereby modulate NAFLD susceptibility. Recent meta-analysis of randomized controlled trials suggest that n-3 PUFA supplementation can reduce liver fat and glucose control in patients with NAFLD, at amounts that can be easily obtained through the habitual diet<sup>6</sup>.

121 In the present study of liver-fat discordant MZ twin pairs, a mean n-6: n-3 ratio of 3.2: 1 was 122 associated with normal liver fat content, while a mean ratio of 6.6: 1 was associated with increased 123 liver fat content independent of genetic and familial confounding factors. Dietary advice for 124 preventing and treating NAFLD should focus on shifting consumption away from processed foods

- 125 (such as refined vegetable oils rich in n-6 fatty acid used for deep frying) towards fresh foods (such
- 126 as vegetable oils used in salads), and by increasing fish intake while decreasing meat intake<sup>11</sup>. Our
- 127 findings could have important implications for the dietary management of NAFLD and encourage
- 128 clinical trials to better understand causal relationships and required doses.

#### 129 **Competing interest statement**

130 The authors declare no competing interests.

### 131 Acknowledgements

- 132 KHP was supported by the Academy of Finland (272376, 266286, 314383, and 315035), Finnish
- 133 Medical Foundation, Finnish Diabetes Research Foundation, Novo Nordisk Foundation, Gyllenberg
- Foundation, Sigrid Juselius Foundation, Helsinki University Hospital Research Funds, Government
- Research Funds and University of Helsinki. LHB received a working grant from the Juho Vainio
- 136 Foundation.

# 137 **References**

- 138 1. Angulo P. Nonalcoholic Fatty Liver Disease. *N Engl J Med.* 2002;346(16):1221-1231.
- 139 2. Tarnoki AD, Tarnoki DL, Bata P, et al. Heritability of non-alcoholic fatty liver disease and
  140 association with abnormal vascular parameters: a twin study. *Liver international: Official*141 *Journal of the International Association for the Study of the Liver.* 2012;32(8):1287-1293.
- Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J
   *Gastroenterol.* 2018;53(3):362-376.
- 4. Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: the good and the bad. *Clin Nutr.* 2014;33(2):186-190.
- 1465.Romero-Gomez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical147activity and exercise. J Hepatol. 2017;67(4):829-846.
- 148 6. Yan JH, Guan BJ, Gao HY, Peng XE. Omega-3 polyunsaturated fatty acid supplementation
  149 and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials.
  150 *Medicine (Baltimore)*. 2018;97(37):e12271.
- 151 7. Naukkarinen J, Heinonen S, Hakkarainen A, et al. Characterising metabolically healthy
  152 obesity in weight-discordant monozygotic twins. *Diabetologia*. 2014;57(1):167-176.
- 153 8. Kaprio J. The Finnish Twin Cohort Study: an update. *Twin Res Hum Genet*.
  154 2013;16(1):157-162.
- Graner M, Seppala-Lindroos A, Rissanen A, et al. Epicardial fat, cardiac dimensions, and
   low-grade inflammation in young adult monozygotic twins discordant for obesity. *Am J Cardiol.* 2012;109(9):1295-1302.
- 158 10. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual
  physical activity in epidemiological studies. *Am J Clin Nutr.* 1982;36(5):936-942.
- 160 11. Simopoulos AP. An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk
  161 for Obesity. *Nutrients*. 2016;8(3):128.
- 162 12. Watson H, Mitra S, Croden FC, et al. A randomised trial of the effect of omega-3
  163 polyunsaturated fatty acid supplements on the human intestinal microbiota. *Gut.*164 2018;67(11):1974-1983.
- 165

		Twin pairs discordant for liver fat (within- pair difference in liver fat $> 5\%$ ) <sup>1</sup>		
	All twins	A	Co-twins with liver $fat > 5\%$	p- value <sup>2</sup>
Demographic factors				
Number (n) of individuals <sup>3</sup>	100	10	10	
Males (n)	46	6	6	
Liver fat $>5\%$ (n)	22	0	10	
Liver fat (%) <sup>4</sup>	1.0 (0.5, 3.9)	1.1 (0.8, 3.2)	9.4 (7.3, 9.4)	
Clinical parameters <sup>4</sup>				
BMI (kg/m <sup>2</sup> )	26.6 (23.7, 29.8)	25.7 (22.9, 27.8)	31.8 (27.6, 35.0)	0.005
Body fat (%)	32.4 (26.9, 40.7)	27.7 (21.2, 38.8)	38.3 (31.9, 43.4)	0.007
Intra-abdominal fat (dm <sup>3</sup> )	807 (422, 1355)	604 (439, 11165)	1709 (1416, 2417)	0.007
Subcutaneous fat (dm <sup>3</sup> )	3727 (2449, 5513)	3263 (2150, 5498)	5768 (3195, 6965)	0.007
LDL-cholesterol (mmol/l)	2.7 (2.3, 3.2)	2.7 (2.5, 2.9)	3.3 (2.7, 3.8)	0.07
HDL-cholesterol (mmol/l)	1.4 (1.2, 1.7)	1.5 (1.3, 1.7)	1.2 (1.1, 1.4)	0.02
Triglycerides (mmol/l)	1.0 (0.7, 1.3)	0.7 (0.5, 1.1)	1.3 (1.0, 2.2)	0.01
HOMA-IR index	1.4 (0.8, 2.0)	1.1 (0.5, 1.8)	2.4 (1.8, 2.8)	0.01
Systolic blood pressure (mmHg)	124 (118, 138)	131 (122, 140)	139 (124, 148)	0.36
Diastolic blood pressure (mmHg)	70 (65, 80)	70 (70, 78)	79 (70, 80)	0.18
Physical activity <sup>4</sup>				
Sports activity index	2.8 (2.3, 3.5)	3.3 (2.3, 4)	2.4 (1.8, 3.5)	0.33
Leisure time activity index	2.8 (2.5, 3.3)	2.8 (2.5, 3.0)	2.9 (2.5, 3.3)	>0.99
Work activity index	2.5 (2.0, 3.3)	2.3 (2.1, 3.0)	2.6 (1.9, 2.9)	0.14
Total energy intake (kcal) <sup>4</sup>	2075 (1774, 2551)	2169 (1809, 2382)	2611 (2319, 2800)	0.07
Macronutrient intake (% energy intake) <sup>4</sup>				
Carbohydrates	43.1 (38.3, 48.1)	43.5 (37.9, 50.0)	37.4 (33.4, 44.0)	0.09
Protein	16.5 (14.8, 18.8)	18.0 (14.2, 22.9)	16.0 (14.1, 18.9)	0.24
Total fat	35.2 (30.6, 39.0)	32.4 (26.3, 38.9)	39.0 (31.6, 42.8)	0.11
Sucrose	9.7 (6.0, 13.0)	4.8 (3.8, 7.0)	8.8 (7.9, 11.2)	0.04
Saturated fatty acids	13.5 (11.1, 16.2)	11.3 (10.9, 13.8)	13.1 (10.7, 16.3)	0.58
Monounsaturated fatty acids	10.6 (9.0, 12.3)	8.8 (7.4, 12.8)	12.0 (9.6, 13.4)	0.24
Polyunsaturated fatty acids	4.5 (3.8, 5.8)	4.1 (3.5 5.5)	5.6 (4.8, 5.8)	0.09
Omega-6/omega-3 ratio <sup>4</sup>	4.8 (3.0, 6.1)	3.2 (2.3, 5.4)	6.6 (3.8, 7.4)	0.005

Table 1. Clinical characteristics, physical activity and macronutrient intakes of the monozygotic twins

Abbreviations: BMI, body mass index; LDL, low-density lipoprotein; HDL, high -density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance

<sup>1</sup>Discordance was defined as the liver fat percentage of one twin  $\leq 5\%$  and the liver fat percentage of his/her co-twin > 5% and a within-pair difference in liver fat of > 5%. The difference in liver fat percentage between discordant co-twins ranged from 5 to 20%.

 $^{2}P$ -values are from Wilcoxon signed rank test comparing co-twins discordant for liver fat.

<sup>3</sup>The 100 monozygotic twin individuals are from 50 complete twin pairs of which 10 twin pairs are

discordant for liver fat.

<sup>4</sup>Data are median and interquartile ranges.

Dependent variable: Within-pair	Unstandardized beta	Standard	Standardized beta	p-value
difference ( $\Delta$ ) in log liver fat	coefficient	error	coefficient	
Sex (Female twin pairs)	-0.57	0.23	-0.31	0.017
Age of the twin pairs (years)	-0.02	0.02	-0.09	0.42
$\Delta$ Omega-6/omega-3 ratio	0.24	0.06	0.43	0.001
$\Delta$ Total energy intake (per 100	0.00	0.02	-0.02	0.83
kcal)				
$\Delta$ Body mass index (kg/m <sup>2</sup> )	0.10	0.03	0.42	0.003
$\Delta$ Alcohol intake (% energy	-0.02	0.02	-0.12	0.30
intake)				
$\Delta$ Sports activity index	-0.14	0.10	-0.17	0.17
<b>R<sup>2</sup>=0.49</b>				

**Table 2.** Multiple linear regression analysis predicting (log transformed) liver fat within 50 pairs of monozygotic twins



